

Advanced Cytometry Techniques for Immune-Based Therapy Analysis

Jonah Riddell¹, Daryl Cole², Alpana Prajapat² and Nicola Bevan²

1 - Sartorius, Marlborough, NA
2 - Sartorius, Royston, UK; Corresponding author: Daryl.Cole@Sartorius.com


Introduction

- As interest in CAR-T cells and immune-based oncology therapies rises, efficient phenotyping of cell therapy products becomes essential. This involves analyzing surface markers associated with cell type characteristics.
- To address this need, tools for panel design and instruments for cell interrogation must be compatible.
- This study highlights the combined use of an advanced panel builder to

- simplify assay creation with quantification using the iQue® HTS Cytometer Platform.
- To showcase this workflow, data was generated for a T cell phenotyping panel and tested in PBMCs.
- In summary, the panel design tool, and the iQue® HTS Platform streamlines the creation of flexible panels for profiling immune cells.

High-Throughput Screening by Cytometry

- Scientists use flow cytometry to investigate complex biological processes as part of routine cell analysis workflows.
- To keep pace with market demands, scientists need a faster way to generate biologically relevant data from high-throughput research workflows.
- The iQue® Platform combines the ability to run complex panels using both cells and beads in the same well with the speed and throughput required for HTS workflows.
- The iQue® 5 instrument is an evolution, building on the established features to enhance the customer experience and support extra flexibility.



- Equipped with adaptable automation capabilities, it facilitates seamless integration with automation solutions, enhancing high-throughput screening and minimizing the need for manual intervention.
- Accelerated market-leading speed with the use of the patented air gap technology to deliver 384-well sampling in <20 min, 96-well <5 min.
- The platform is available in both a 3 laser (Violet, Blue, Red) and 4 laser (Violet, Yellow, Blue, Red) format for improved flexibility and easier panel design to enable greater workflow support.
- VBR format with up to 19 channel capacity.
- VYBR format with up to 27 channel capacity.
- Improved Clog detection and management with air-gap sensor for simplified monitoring.
- Easily set individual channel gains with SiPM.
- Improved usability, fluidics and data analytics including higher volume acquired in less time with reduced carry over between samples.

| Emission Filter | Laser | | | |
|-----------------|----------------|-----------------|----------------|-----------|
| | 405 nm | 488 nm | 561 nm * | 640 nm |
| 445/45 nm | ✓ Pacific Blue | | | |
| 525/45 nm | ✓ BV510 | ✓ FITC | | |
| 586/20 nm | ✓ BV605 | ✓ EYFP | ✓ PE | |
| 615/20 nm | ✓ Qdot 605 | ✓ PI | ✓ PE-Dazzle594 | |
| 667/30 nm | ✓ BV650 | ✓ PerCP | ✓ PE-Cy5 | ✓ APC |
| 695/40 nm | ✓ BV711 | ✓ PerCP-Cy5.5 | ✓ PE-Cy5.5 | ✓ AF680 |
| 725/40 nm | ✓ BV750 | ✓ PerCP-eFluor7 | ✓ PE-AF700 | ✓ AF700 |
| 780/60 nm | ✓ BV786 | ✓ PE-Cy7 | ✓ PE-Cy7 | ✓ APC-Cy7 |



Laser and channel details for iQue® 5 Platform * 561 nm not on 3 laser (VBR) instrument

T Cell Panel Design

A comprehensive T cell panel was developed using the iQue® Cytometry Panel Builder (link can be found on our website).

- Panel builder has simple steps to guide you through building the panel, powered by Easy Panel.
- Two panels were designed for use on either iQue® 3 or 5 using a base panel covering CD3, CD4, CD8 and a viability marker.
- Further markers for activation (CD69, CD25), exhaustion (LAG-3, TIM-3, PD-1) or memory (CCR7, CD62L), were added for further characterization.
- Using the iQue® 5 HTS platform a further 4 markers were incorporated to enable the capture of 11 data channels, along with forward and side scatter, from a 96-well plate.
- The addition of a fourth laser increases the flexibility for panel design and ability to capture more data.




| Laser | Channel | Target | Fluorochrome | iQue® 3 panel |
|------------|---------|-----------|---------------|---------------|
| Violet 405 | V445/45 | Viability | Zombie Violet | VL1 – 445/45 |
| Violet 405 | V525/45 | CD8 | BV510 | VL2 – 530/30 |
| Violet 405 | V615/20 | CD4 | BV605 | VL4 – 615/24 |
| Violet 405 | V780/60 | CD69 | BV786 | |
| Blue 488 | B525/45 | CD62L | FITC | |
| Yellow 561 | Y586/20 | CD25 | PE | BL2 – 572/28 |
| Yellow 561 | Y615/20 | CCR7 | PD-Dazzle594 | |
| Yellow 561 | Y780/60 | PD-1 | PECy7 | BL5 – 780/60 |
| Red 640 | R667/30 | LAG-3 | AF647 | RL1 – 675/30 |
| Red 640 | R695/30 | TIM-3 | APC | |
| Red 640 | R780/60 | CD3 | APC-Fire750 | RL2 - 780/60 |



Compensation Assessment

Initially, compensation particles were tested with the selected antibodies to automatically calculate compensation spillover values using iQue Forecyt® software, before applying the panel to immune cells.

- In iQue® 5, PE conjugated antibodies can use the yellow laser excitation for improved resolution.
- Spillover matrix highlights potential issue with TIM-3 and LAG-3 due to overlapping spectra.
- iQue Forecyt® compensation allows overlapping fluorophores to be isolated and successfully analyzed.




| Primary Channel | Spillover Channel | CD3 (R695-H) | CD4 (R667-H) | CD8 (R667-H) | CD3 (R695-H) | CD4 (R667-H) | CD8 (R667-H) | CD3 (R695-H) | CD4 (R667-H) | CD8 (R667-H) | CD3 (R695-H) | CD4 (R667-H) | CD8 (R667-H) |
|-----------------|-------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| CD3 (R695-H) | CD3 (R695-H) | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| CD3 (R695-H) | CD4 (R667-H) | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 |
| CD3 (R695-H) | CD8 (R667-H) | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 |
| CD4 (R667-H) | CD3 (R695-H) | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| CD4 (R667-H) | CD4 (R667-H) | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 |
| CD4 (R667-H) | CD8 (R667-H) | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 |
| CD8 (R667-H) | CD3 (R695-H) | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| CD8 (R667-H) | CD4 (R667-H) | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 |
| CD8 (R667-H) | CD8 (R667-H) | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 1.00 |

Phenotype Profiling in PBMCs

Human PBMCs were cultured in RPMI 1640 media with 10% serum and IL-2, with or without CD3/CD28 T cell activation beads (1 bead per cell) to activate the T cell population. Over the following 72 hours, the cells were assessed using the panel.

Cells were assessed using the following strategy:

- All events to detect cells (FSC Vs SSC) and singlets (not shown)
- Viability marker for live cells → Activation – CD69, CD25
- CD3+ cells → Exhaustion – PD-1, LAG-3, TIM-3
- CD4+ and CD8+ populations → Memory – CCR7, CD62L



Conclusion

- In summary, the iQue® 5 HTS platform support users with increased flexibility for designing complex panels, suitable for cell therapy characterization.
- The integration of the panel builder with the iQue® Platform offers a streamlined approach for creating complex panels to profile immune cell populations.
- Panels can be further enhanced by incorporating cytokine profiling using the iQue Qbead® portfolio, leveraging the iQue® Platform's capacity to independently track both cell and bead populations within the same sample.

